Skip to main content
main-content
Top

04-01-2022 | Semaglutide | News

approvalsWatch

Higher semaglutide dose approved in USA

Author: Eleanor McDermid

share
SHARE
print
PRINT
insite
SEARCH

medwireNews: Semaglutide will soon be available at a dose of 2.0 mg in the USA, following FDA approval.

The weekly injectable glucagon-like peptide-1 receptor agonist was previously approved at a maximum dose of 1.0 mg, as used in the main SUSTAIN trial series.

But the more recent SUSTAIN-FORTE trial showed the 2.0 mg dose to produce a significantly larger reduction in glycated hemoglobin than the 1.0 mg dose, forming the basis of this approval.


Juan Pablo Frías discusses whether the findings of SUSTAIN-FORTE will justify an increase in the approved maximum dose of semaglutide for people with type 2 diabetes (3:31).


medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group

share
SHARE
print
PRINT

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

The challenge of type 2 diabetes in children

Who is at the highest risk for developing type 2 diabetes in their youth? 

Supporting people with diabetes during Ramadan

Evidence overview and practical advice for fasting with type 1 or type 2 diabetes